SPRY — ARS Pharmaceuticals Balance Sheet
0.000.00%
- $1.35bn
- $1.04bn
- $89.15m
Annual balance sheet for ARS Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 387 | 254 | 274 | 228 | 314 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | — | — | 9.16 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 391 | 261 | 278 | 232 | 334 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.8 | 6.95 | 0.774 | 0.824 | 1.07 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 395 | 333 | 281 | 233 | 351 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9.6 | 14.9 | 5.44 | 2.39 | 23.4 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 11.9 | 19.7 | 8.55 | 2.43 | 94.4 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 383 | 314 | 273 | 231 | 257 |
Total Liabilities & Shareholders' Equity | 395 | 333 | 281 | 233 | 351 |
Total Common Shares Outstanding |